While Sebert et al. studied patients with germline DDX41 mutations and analyzed the survival of only those patients who were treated for high-risk MDS and AML, Polprasert et al. included all patients with either germline or somatic mutations in the survival analyses. The gene discussed is DDX41; the disease is acute myeloid leukemia.